• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Black Hawk Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    2/19/26 3:13:51 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BKHA alert in real time by email
    false 0002000775 0002000775 2026-02-19 2026-02-19 0002000775 bkhau:UnitsEachConsistingOfOneOrdinaryShareAndOneFiftyOfOneRightMember 2026-02-19 2026-02-19 0002000775 bkhau:OrdinarySharesParValue0.0001PerShareMember 2026-02-19 2026-02-19 0002000775 bkhau:RightsEachRightEntitlingHolderToReceiveOneOrdinaryShareMember 2026-02-19 2026-02-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or Section 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report: February 19, 2026

     

    Black Hawk Acquisition Corporation

    (Exact name of registrant as specified in its charter)

     

    Cayman Islands   6770001-41984   00-0000000N/A

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    4125 Blackhawk Plaza Circle, Suite 166 

    Danville, CA

      94506
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (952) 217-4482

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of exchange on which registered
    Units, each consisting of one ordinary share and one-fifth of one right   BKHAU   The Nasdaq Stock Market LLC
    Ordinary shares, par value $0.0001 per share   BKHA   The Nasdaq Stock Market LLC
    Rights, each right entitling the holder to receive one ordinary share   BKHAR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

       

     

     

    Item 1.01 Entry Into a Material Definitive Agreement.

     

    On February 12, 2026, Black Hawk Acquisition Corp., a Cayman Islands exempted company (the “Company”), issued a convertible promissory note (the “Note”) in the principal amount of up to $300,000 to Black Hawk Management LLC (the “Sponsor”). The Note was issued in connection with advances the Sponsor has made, and may make in the future, to the Company for working capital expenses. 

     

    The Note bears interest at a rate of 10% per annum and is due and payable upon the occurrence of (i) the closing of the Company’s initial business combination (a “DeSPAC Transaction”) or (ii) the liquidation of the Company. In the event of a liquidation, all amounts due under the Note will be repaid in cash. In the event of a DeSPAC Transaction, the Sponsor may elect to receive repayment in cash or to convert the outstanding principal balance of the Note into ordinary shares of the post-business combination company at a conversion price of $1.00 per share.

     

    If converted, the number of shares issuable will equal the portion of the principal amount being converted divided by $1.00, rounded up to the nearest whole share. The conversion shares will be entitled to registration rights and the holders will enter into a registration rights agreement with the post-DeSPAC company consistent with the Company’s existing registration rights agreement.

     

    The issuance of the Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”).

     

    The foregoing description is qualified in its entirety by reference to the Note, a copy of which is attached as Exhibit 10.1 hereto and is incorporated herein by reference.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The disclosure set forth above under Item 1.01 is incorporated herein by reference.

     

    Item 3.02 Unregistered Sales of Equity Securities.

     

    To the extent the Note may be converted into ordinary shares upon the closing of a DeSPAC Transaction, such shares will be issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, as a transaction not involving a public offering.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.  Description
    10.1  Promissory Note, dated February 12, 2026, issued by Black Hawk Acquisition Corporation to Black Hawk Management LLC
    104  Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     1 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Black Hawk Acquisition Corporation
         
    Date: February 19, 2026 By: /s/ Kent Louis Kaufman
      Name: Kent Louis Kaufman
      Title: Chief Executive Officer

     

     2 
    Get the next $BKHA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BKHA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BKHA
    SEC Filings

    View All

    SEC Form 10-Q filed by Black Hawk Acquisition Corporation

    10-Q - Black Hawk Acquisition Corp (0002000775) (Filer)

    4/20/26 6:23:25 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form NT 10-Q filed by Black Hawk Acquisition Corporation

    NT 10-Q - Black Hawk Acquisition Corp (0002000775) (Filer)

    4/14/26 4:14:17 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Hawk Acquisition Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Black Hawk Acquisition Corp (0002000775) (Filer)

    4/1/26 4:56:37 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BKHA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

    BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (NASDAQ:BKHA, BKHAU, BKHAR)), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader with deep industry experience, as Chief Executive Officer (CEO), effective March 17, 2026. He succeeds Founder and CEO Luo Feng, Ph.D., who has been appointed Chief Scientific Officer. "Dr. Tolentino

    3/18/26 10:42:50 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BKHA
    Leadership Updates

    Live Leadership Updates

    View All

    Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

    BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (NASDAQ:BKHA, BKHAU, BKHAR)), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader with deep industry experience, as Chief Executive Officer (CEO), effective March 17, 2026. He succeeds Founder and CEO Luo Feng, Ph.D., who has been appointed Chief Scientific Officer. "Dr. Tolentino

    3/18/26 10:42:50 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BKHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Black Hawk Acquisition Corporation

    SC 13G/A - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/15/24 9:17:26 AM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Black Hawk Acquisition Corporation

    SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/14/24 8:39:26 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Black Hawk Acquisition Corporation

    SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/14/24 6:13:30 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care